Cytokinetics, Incorporated (NASDAQ:CYTK) is a prominent biopharmaceutical company dedicated to the development of innovative treatments based on muscle biology for serious diseases such as heart failure and amyotrophic lateral sclerosis (ALS). Competing in the dynamic biotech industry against giants like Amgen and Biogen, Cytokinetics has recently been in the spotlight due to significant insider trading activity by its Executive Vice President, Andrew Callos.
On January 5, 2026, Andrew Callos executed a notable sale of 15,000 shares of CYTK at $60.28 each, reducing his holdings to 50,440 shares. Callos's active trading in December included the sale of 1,042 shares at $65.96 on December 8th and a significant sale of 52,486 shares at $65.95 on December 5th, totaling approximately $3.46 million. These transactions have been transparently reported in SEC filings, offering insights to investors.
The current market price of CYTK stands at $61.26, with a slight decrease of 0.76% or $0.47. The stock has demonstrated volatility, with a yearly high of $70.98 and a low of $29.31. Cytokinetics boasts a market capitalization of approximately $7.29 billion, with a trading volume of 2,252,943 shares.
